Reducing systemic dose whilst enhancing efficacy
- Challenge: Minimising immuno-oncology toxicity
The efficacy of many immuno-oncology therapies is limited by delivery, distribution and penetration into solid tumours. Image-guided device-based (e.g. ultrasound) and antibody re-formulation strategies have improved delivery and therapeutic responses. Based on prior device-enhanced oncological drug delivery trials, such as TarDox, and in collaboration with industrial partners (OxSonics Therapeutics, Takeda, AstraZeneca), this project is seeking to optimise delivery and distribution at reduced systemic doses across a range of solid tumours and emerging immuno-oncology therapeutics.